Analyst Kyle Mikson CFA from Canaccord Genuity reiterated a Buy rating on Guardant Health and keeping the price target at $65.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kyle Mikson CFA has given his Buy rating due to a combination of factors that highlight Guardant Health’s potential for growth and innovation. The company is expected to showcase significant advancements during its upcoming investor day, particularly in its minimal residual disease and tissue-based therapy selection businesses. These areas are poised for accelerated adoption, which could drive future revenue growth.
Moreover, Guardant Health’s recent developments in colorectal cancer screening, specifically the Shield V2 test, and its ambitious financial targets for 2028, including a revenue CAGR of over 30%, further support the Buy rating. The company’s emphasis on data and AI to enhance precision medicine also positions it well for long-term success. Despite some mixed data outcomes, the overall outlook remains positive, with the potential for substantial updates and strategic advancements in the near future.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $70.00 price target.